cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

doi:10.1007/s00401-020-02127-9

. 2020 Mar;139(3):603-608.

doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Daniel J Brat¹, Kenneth Aldape², Howard Colman³, Dominique Figrarella-Branger⁴, Gregory N Fuller⁵, Caterina Giannini⁶, Eric C Holland⁷, Robert B Jenkins⁶, Bette Kleinschmidt-DeMasters⁸, Takashi Komori⁹, Johan M Kros¹⁰, David N Louis¹¹, Catriona McLean¹², Arie Perry¹³, Guido Reifenberger^{14

15}, Chitra Sarkar¹⁶, Roger Stupp¹⁷, Martin J van den Bent¹⁸, Andreas von Deimling^{19

20}, Michael Weller²¹

Affiliations

¹ Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA. Daniel.brat@northwestern.edu.
² Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
³ Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
⁴ Service d'Anatomie Pathologique et de Neuropathologie, Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Marseille, France.
⁵ Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁷ Division of Human Biology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
⁸ Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
⁹ Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
¹⁰ Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
¹¹ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
¹² Alfred Anatomical Pathology and NNF, Victorian Brain Bank, Carlton, VIC, Australia.
¹³ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
¹⁴ Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
¹⁵ German Cancer Consortium (DKTK), Partner site Essen/Düsseldorf, Düsseldorf, Germany.
¹⁶ Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
¹⁷ Robert H. Lurie Cancer Center, Malnati Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
¹⁸ Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
¹⁹ Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
²⁰ Clinical Cooperation Unit Neuropathology, German Cancer Institute (DKFZ), Heidelberg, Germany.
²¹ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

PMID: 31996992
PMCID: PMC8443062
DOI: 10.1007/s00401-020-02127-9

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Daniel J Brat et al. Acta Neuropathol. 2020 Mar.

. 2020 Mar;139(3):603-608.

doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.

Authors

Affiliations

¹ Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA. Daniel.brat@northwestern.edu.
² Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
³ Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
⁴ Service d'Anatomie Pathologique et de Neuropathologie, Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Marseille, France.
⁵ Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁷ Division of Human Biology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
⁸ Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
⁹ Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
¹⁰ Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
¹¹ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
¹² Alfred Anatomical Pathology and NNF, Victorian Brain Bank, Carlton, VIC, Australia.
¹³ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
¹⁴ Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
¹⁵ German Cancer Consortium (DKTK), Partner site Essen/Düsseldorf, Düsseldorf, Germany.
¹⁶ Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
¹⁷ Robert H. Lurie Cancer Center, Malnati Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
¹⁸ Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
¹⁹ Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
²⁰ Clinical Cooperation Unit Neuropathology, German Cancer Institute (DKFZ), Heidelberg, Germany.
²¹ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

PMID: 31996992
PMCID: PMC8443062
DOI: 10.1007/s00401-020-02127-9

No abstract available

PubMed Disclaimer

Comment in

The IMPACT of Molecular Grading of Gliomas on Contemporary Clinical Practice.
Milano MT, Chan MD, Minniti G, Hattangadi-Gluth JA, Redmond KJ, Soltys SG. Milano MT, et al. Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):859-862. doi: 10.1016/j.ijrobp.2020.05.043. Int J Radiat Oncol Biol Phys. 2020. PMID: 32698972 No abstract available.

Cited by

The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
Di Nunno V, Aprile M, Bartolini S, Gatto L, Tosoni A, Ranieri L, De Biase D, Asioli S, Franceschi E. Di Nunno V, et al. Cells. 2023 Dec 25;13(1):44. doi: 10.3390/cells13010044. Cells. 2023. PMID: 38201248 Free PMC article. Review.
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Miller JJ, et al. Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207. Neuro Oncol. 2023. PMID: 36239925 Free PMC article.
Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
Gundogdu F, Babaoglu B, Soylemezoglu F. Gundogdu F, et al. J Neuropathol Exp Neurol. 2024 Jan 19;83(2):107-114. doi: 10.1093/jnen/nlad109. J Neuropathol Exp Neurol. 2024. PMID: 38109891 Free PMC article.
Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging.
Hempel JM, Brendle C, Adib SD, Behling F, Tabatabai G, Castaneda Vega S, Schittenhelm J, Ernemann U, Klose U. Hempel JM, et al. J Clin Med. 2021 May 26;10(11):2325. doi: 10.3390/jcm10112325. J Clin Med. 2021. PMID: 34073442 Free PMC article.
Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.
Zakharova G, Efimov V, Raevskiy M, Rumiantsev P, Gudkov A, Belogurova-Ovchinnikova O, Sorokin M, Buzdin A. Zakharova G, et al. Int J Mol Sci. 2022 Dec 21;24(1):157. doi: 10.3390/ijms24010157. Int J Mol Sci. 2022. PMID: 36613601 Free PMC article.

See all "Cited by" articles

References

1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al. (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20: 66–77 Doi 10.1093/neuonc/nox132 - DOI - PMC - PubMed
1. Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al. (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Onc 21: 1519–1528 Doi DIO 10.1093/neuonc/noz124 - DOI - PMC - PubMed
1. Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS et al. (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 139: 175–192 Doi 10.1007/s00401-019-02067-z - DOI - PubMed
1. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136: 805–810 Doi 10.1007/s00401-018-1913-0 - DOI - PMC - PubMed
1. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372: 2481–2498 Doi 10.1056/NEJMoa1402121 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al. (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20: 66–77 Doi 10.1093/neuonc/nox132 - DOI - PMC - PubMed

[2] Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al. (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20: 66–77 Doi 10.1093/neuonc/nox132 - DOI - PMC - PubMed

[3] Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al. (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Onc 21: 1519–1528 Doi DIO 10.1093/neuonc/noz124 - DOI - PMC - PubMed

[4] Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al. (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Onc 21: 1519–1528 Doi DIO 10.1093/neuonc/noz124 - DOI - PMC - PubMed

[5] Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS et al. (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 139: 175–192 Doi 10.1007/s00401-019-02067-z - DOI - PubMed

[6] Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS et al. (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 139: 175–192 Doi 10.1007/s00401-019-02067-z - DOI - PubMed

[7] Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136: 805–810 Doi 10.1007/s00401-018-1913-0 - DOI - PMC - PubMed

[8] Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136: 805–810 Doi 10.1007/s00401-018-1913-0 - DOI - PMC - PubMed

[9] Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372: 2481–2498 Doi 10.1056/NEJMoa1402121 - DOI - PMC - PubMed

[10] Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372: 2481–2498 Doi 10.1056/NEJMoa1402121 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Affiliations

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Authors

Affiliations

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous